SPA
UTMD icon

Sherbrooke Park Advisers’s Utah Medical Products UTMD Stock Holding History

Sherbrooke Park Advisers’s Portfolio UTMD Stock Details UTMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5,064
Closed -$360K – 1218
2024
Q1 		$360K Buy
+5,064
New +$380K 0.07% 491

Other funds holding UTMD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Sherbrooke Park Advisers's UTMD Position: Q2 2024 in Review

Sherbrooke Park Advisers sold out of Utah Medical Products (UTMD) in Q2 2024, closing a stake of 5,064 shares — an estimated $360K sold.

Sherbrooke Park Advisers first reported a position in UTMD in Q1 2024 and held it in 1 quarter. The position peaked at $360K in Q1 2024. 100 funds tracked by Wall St. Rank hold UTMD as of Q2 2024.

  • Sherbrooke Park Advisers reported no remaining Utah Medical Products position as of Q2 2024 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 5,064 Utah Medical Products shares in Q2 2024, an estimated $360K.
  • Sherbrooke Park Advisers first reported a position in Utah Medical Products in Q1 2024 and held it in 1 quarter.
  • Sherbrooke Park Advisers's Utah Medical Products position peaked at $360K in Q1 2024.
  • 100 funds tracked by Wall St. Rank held Utah Medical Products as of Q2 2024.

Based on Sherbrooke Park Advisers's 13F filing for Q2 2024, filed 14 Aug 2024.